Offers New Storage Options for Cell and Gene Therapies
Marken is to double the space of its GMP facility in Frankfurt to further expand its frozen room storage capabilities in anticipation of the COVID-19 vaccine and storage needs. Marken’s expansion of its facilities in Frankfurt will add an additional 1,485 m2 of space, increasing total available space for client materials to over 3,715 m2. This additional space is expected to be fully operational by October, 2020.
Cell and gene therapies are a strategic focus for Marken due to their high complexity and the exacting quality standards they require, both in transport and storage. In addition to the growing need for cryogenic storage, Marken’s expansion of the Frankfurt facility is driven by the high demand to provide up to -80C storage for future vaccines and treatments.
In addition, Marken is proud to announce the integration of its cryogenic storage services which went live in June in both Frankfurt and Philadelphia. These latest additions to the Marken GMP network service portfolio further reinforces the Company’s dedication to serving its clients as a complete, end-to-end service provider. Future cryogenic storage locations will include the APAC region.
Offering a comprehensive cryogenic transport and storage solution enables cell and gene therapy companies to simplify their supply chain by allowing them to consolidate processes with Marken, an established and trusted service provider. Fewer handoffs mean fewer variables, less risk and an unbroken chain of custody.